TCGA-PL-A8LY-01A-11R-A41B-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- MYC_TARGETS_V2+0.390
- KRAS_SIGNALING_DN+0.260
- MYC_TARGETS_V1+0.170
- PANCREAS_BETA_CELLS+0.170
- APICAL_JUNCTION+0.140
- P53_PATHWAY+0.140
- DNA_REPAIR+0.110
- MYOGENESIS+0.110
- NOTCH_SIGNALING+0.090
Top 10 suppressed
- PROTEIN_SECRETION-0.550
- MITOTIC_SPINDLE-0.450
- G2M_CHECKPOINT-0.420
- INTERFERON_ALPHA_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- MTORC1_SIGNALING-0.410
- E2F_TARGETS-0.370
- TGF_BETA_SIGNALING-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
- ANDROGEN_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.863 |
| 2 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.850 |
| 3 | TCGA-CF-A47T-01A-11R-A23W-07 | — | — | 0.846 |
| 4 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.830 |
| 5 | TCGA-AO-A0JB-01A-11R-A32Y-07 | — | B | 0.803 |
| 6 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.801 |
| 7 | SRR650198 | — | — | 0.800 |
| 8 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.790 |
| 9 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.787 |
| 10 | d2c9b21d-0f64-4182-9d5d-82b80a158a1f | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |